Cartesian Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $181.55M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | Before market open | – | $0.46 | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | Before market open | $78.00K | $-1.46 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 9, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | Before market open | $452.00K | $-1.38 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | Before market open | $298.00K | $0.50 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | Before market open | $1.10M | $-0.68 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 13, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | $387.00K | $-1.13 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 7, 2024 | Before market open | – | – | – |
Press releases
Announcements Cartesian Therapeutics filed with the SEC
Cartesian Therapeutics Announces Additional Retreatment Data for Descartes-08 Highlighting Deep and Durable Responses in Patients with Myasthenia Gravis
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform
Regulation FD disclosure · EX-99.1 to Form 8-K
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
Material agreement · New financial obligation · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Pioneering mRNA Cell Therapy for Autoimmunity May 2026
Material agreement · New financial obligation · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Pioneering mRNA Cell Therapy for Autoimmunity January 2026 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook
Regulation FD disclosure · EX-99.2 to Form 8-K
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Pioneering mRNA Cell Therapy for Autoimmunity November 2025 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors
Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Pioneering mRNA Cell Therapy for Autoimmunity April 2025 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Pioneering mRNA Cell Therapy for Autoimmunity March 2025 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis
Other events · EX-99.1 to Form 8-K
Pioneering mRNA Cell Therapy for Autoimmunity January 2025 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune Diseases
Regulation FD disclosure · EX-99.2 to Form 8-K
Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Updated Data from Phase 2b Trial of Descartes-08 in Myasthenia Gravis December 3, 2024
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
® THERAPEUTICS Pioneering mRNA Cell Therapy for Autoimmunity August 2024 C A R T E S I A N T H E R A P E U T I C S Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Topline Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
® THERAPEUTICS Pioneering mRNA Cell Therapy for Autoimmunity May 2024 C A R T E S I A N T H E R A P E U T I C S Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
® THERAPEUTICS Pioneering mRNA Cell Therapy for Autoimmunity April 2024 C A R T E S I A N T H E R A P E U T I C S Exhibit 99.1
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick,
Material agreement · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
® THERAPEUTICS Pioneering mRNA Cell Therapy for Autoimmunity January 2024 C
Regulation FD disclosure · EX-99.1 to Form 8-K